| Parameters |
All subjects n=100 |
Active LN n=47 |
Inactive LN n=53 |
p value |
| Female, no. (%) |
92 (92) |
43 (91.5) |
49 (92.5) |
0.57 |
| Male, no. (%) |
8 (8) |
4 (8.5) |
4 (7.5) |
|
| Race, no. (%) |
|
|
|
|
| -Malay |
41(41) |
24 (51.1) |
17 (32.1) |
0.14 |
| -Chinese |
55 (55) |
21 (44.7) |
34 (64.2) |
|
| -Indian |
4 (4) |
2 (4.3) |
2 (3.8) |
|
| Age, mean ± SD years |
36.90 ± 10.62 |
36.40 ± 9.97 |
37.33 ± 11.24 |
0.74 |
| LN duration (years) |
7 (1-24) |
7 (1-24) |
7 (1-17) |
0.56 |
| Median (IQR) |
|
|
|
|
| Biopsy-proven LN, no. (%) |
|
|
|
|
| - WHO class I |
1 (1) |
1 (2.1) |
0 (0) |
|
| - WHO class II ± V |
6 (6) |
3 (6.4) |
3 (5.7) |
|
| - WHO class III ± V |
34 (34) |
15 (31.9) |
19 (35.8) |
|
| - WHO class IV ± V |
52 (52) |
26 (55.3) |
26 (49.1) |
|
| - WHO class V |
5 (5) |
1 (2.1) |
4 (7.5) |
0.71 |
| - WHO class VI |
2 (2) |
1 (2.1) |
1 (1.9) |
|
| Activity index median (IQR) |
8 (0-19) |
9 (0-16) |
8 (0-19) |
0.93 |
| Chronicity index median (IQR) |
3 (0-15) |
3.58 (0-9) |
3 (1-15) |
0..55 |
| CKD stage |
|
|
|
|
| -Stage 1 (eGFR >90) |
61 (61) |
25 (53.2) |
36 (67.9) |
|
| -Stage 2 (eGFR 60-89) |
22 (22) |
10 (21.3) |
12 (22.6) |
0.06 |
| -Stage 3 (eGFR30-59) |
14 (14) |
9 (19.1) |
5 (9.4) |
|
| -Stage 4 (eGFR15-29) |
3 (3) |
3 (6.4) |
0 (0%) |
|
Continuous variables were calculated by Mann-Whitney U test or Kruskal-Wallis
test, and categorical variables by Pearson’s chi-square test. SD: Standard
Deviation; IQR: Interquartile Range. |
